Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Amphotericin B (AmB) has been the most effective systemic antifungal agent, but its use is limited by the dose-limiting toxicity of the conventional micellar dispersion formulation (Fungizone). New formulations with better and improved safety profiles are being developed and include ABELCET (formerly ABLC), but their dispositions have not been well characterized; hence, the reason for their improved profiles remains unclear. This report details the pharmacokinetics of ABELCET examined in various pharmacokinetic and efficacy studies by using whole-blood measurements of AmB concentration performed by high-pressure liquid chromatography. The data indicated that the disposition of AmB after administration of ABELCET is different from that after administration of Fungizone, with a faster clearance and a larger volume of distribution. It exhibits complex and nonlinear pharmacokinetics with wide interindividual variability, extensive distribution, and low clearance. The pharmacokinetics were unusual. Clearance and volume of distribution were increased with dose, peak and trough concentrations after multiple dosings increased less than proportionately with dose, steady state appeared to have been attained in 2 to 3 days, despite an estimated half-life of up to 5 days, and there was no evidence of significant accumulation in the blood. The data are internally consistent, even though they were gathered under different conditions and circumstances. The pharmacokinetics of ABELCET suggest that lower concentrations in blood due to higher clearance and greater distribution may be responsible for its improved toxicity profile compared to those of conventional formulations.
Adedoyin
A
A
Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pennsylvania 15213-2582, USA.
Bernardo
J F
JF
Swenson
C E
CE
Bolsack
L E
LE
Horwith
G
G
DeWit
S
S
Kelly
E
E
Klasterksy
J
J
Sculier
J P
JP
DeValeriola
D
D
Anaissie
E
E
Lopez-Berestein
G
G
Llanos-Cuentas
A
A
Boyle
A
A
Branch
R A
RA
D000666:Amphotericin B / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000009:adverse effects; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004338:Drug Combinations; D004347:Drug Interactions; D015658:HIV Infections / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism; D007897:Leishmaniasis, Mucocutaneous / Q000378:metabolism; D009181:Mycoses / Q000378:metabolism; D009503:Neutropenia / Q000378:metabolism; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D012016:Reference Values
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B